Liposomalization of SN-38 as active metabolite of CPT-11
- PMID: 16182400
- DOI: 10.1016/j.jconrel.2005.08.023
Liposomalization of SN-38 as active metabolite of CPT-11
Abstract
Although many drugs have been developed for the treatment of disease, some drugs have complications such as adverse effects, and antitumor agents should target tumors or cells more selectively. It is therefore necessary to develop drug delivery systems, and liposomes are reportedly useful as an effective drug carrier. An antitumor agent, CPT-11, inhibits DNA synthesis by the inhibition of topoisomerase1 and has a strong antitumor activity. SN-38 is converted from CPT-11 as an active metabolite by carboxylesterase in the liver. As SN-38 is insoluble, it has not been applied at the clinical stage as an injection. It is expected that SN-38 liposomalization may increase its usefulness in cancer chemotherapy. Our purpose is to have a clinical application of SN-38 by a novel method of liposomalization to expand the application for the other insolubility drugs. As SN-38 is hydrophobic, SN-38-trapped liposome preparation was attempted using the Bangham method, which is effective for general preparation. However, a high ratio of SN-38 trapped in liposome was not achieved, and this was not improved by the freezing-thawing method or the freeze-drying method. On the other hand, the ratio of SN-38 trapped in liposome by the modified remote loading method was about 4 times that by the Bangham method, and the ratio by the film loading method, novel method of liposomal preparation, reached 2 times and 8 times that by the modified remote loading method and Bangham method, respectively, showing a remarkable increase. In conclusion, it was suggested that the preparation of SN-38 liposome using the film loading method effectively entraps SN-38. Thus, it is expected that SN-38 liposome can be applied as an injection. This preparation method is useful if application is possible in the other insolubility drugs.
Similar articles
-
Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.Cancer Lett. 1998 May 15;127(1-2):99-106. doi: 10.1016/s0304-3835(98)00031-7. Cancer Lett. 1998. PMID: 9619864
-
Effective prodrug liposome and conversion to active metabolite.Curr Drug Metab. 2000 Jul;1(1):31-48. doi: 10.2174/1389200003339225. Curr Drug Metab. 2000. PMID: 11467079 Review.
-
Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.Jpn J Cancer Res. 1999 Feb;90(2):226-32. doi: 10.1111/j.1349-7006.1999.tb00737.x. Jpn J Cancer Res. 1999. PMID: 10189894 Free PMC article.
-
Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.J Control Release. 2009 May 21;136(1):30-7. doi: 10.1016/j.jconrel.2009.01.013. Epub 2009 Jan 24. J Control Release. 2009. PMID: 19331859
-
Preclinical evaluation of CPT-11 and its active metabolite SN-38.Semin Oncol. 1996 Feb;23(1 Suppl 3):11-20. Semin Oncol. 1996. PMID: 8633248 Review.
Cited by
-
The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.Org Lett. 2010 Apr 2;12(7):1384-7. doi: 10.1021/ol1002626. Org Lett. 2010. PMID: 20192275 Free PMC article.
-
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.Int J Nanomedicine. 2017 Aug 1;12:5487-5500. doi: 10.2147/IJN.S133816. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28814865 Free PMC article.
-
One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion.Int J Nanomedicine. 2019 Mar 26;14:2115-2126. doi: 10.2147/IJN.S193783. eCollection 2019. Int J Nanomedicine. 2019. PMID: 30988612 Free PMC article.
-
Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid.J Immunol. 2008 Sep 15;181(6):4177-87. doi: 10.4049/jimmunol.181.6.4177. J Immunol. 2008. PMID: 18768875 Free PMC article.
-
Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling.ACS Nano. 2022 Dec 27;16(12):19722-19754. doi: 10.1021/acsnano.2c07312. Epub 2022 Dec 15. ACS Nano. 2022. PMID: 36520546 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials